Because the individual IL-6 and IL-8 markers show similar clinical significance related to disease progression and survival outcomes in both cancer types, and more importantly their corresponding IL-6/IL-8 ratio does also; examples like these strengthen our premise that comparing clinically relevant inflammatory biomarkers in breast cancer can inform on potentially relevant inflammatory markers in pancreatic cancer that have yet to reach the realm of clinical utility. This evidence concerns the gene IL6 and pancreatic neoplasm.